{"id":23618,"date":"2025-01-28T12:47:54","date_gmt":"2025-01-28T04:47:54","guid":{"rendered":"https:\/\/flcube.com\/?p=23618"},"modified":"2025-01-28T12:47:57","modified_gmt":"2025-01-28T04:47:57","slug":"vigonvita-life-sciences-targets-hkex-ipo-with-integrated-biopharma-model","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23618","title":{"rendered":"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model"},"content":{"rendered":"\n

On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.<\/p>\n\n\n\n

Company Overview and Mission<\/strong>
The prospectus shows that Vigonvita Bio, established in 2013, is an integrated biopharmaceutical company committed to discovering, developing, and commercializing innovative small molecule drugs. Vigonvita Bio’s mission is to improve patients’ health and quality of life through innovation, focusing on meeting the evolving diverse needs of patients in key therapeutic areas, namely (i) viral infections, (ii) neuropsychiatric, and (iii) reproductive health.<\/p>\n\n\n\n

Pipeline and Core Products<\/strong>
Over the past 12 years, Vigonvita Bio has not only built end-to-end capabilities covering the entire industrial value chain of “research – clinical development – manufacturing – commercialization” but also developed an excellent innovation pipeline consisting of nine innovative assets, including three core products: VV116, LV232, and TPN171, each with first-in-class or best-in-class potential.<\/p>\n\n\n\n

Core Product Details<\/strong>
VV116 is an RNA-dependent RNA polymerase (RdRp) inhibitor approved in China and Uzbekistan for the treatment of COVID-19, marketed as Mindive\u00ae and MINDVY\u00ae, respectively, and is currently in Phase II\/III clinical development in China for the treatment of respiratory syncytial virus (RSV) infection.<\/p>\n\n\n\n

LV232 is a potential first-in-class dual-target 5-hydroxytryptamine transporter (5-HTT) \/ 5-hydroxytryptamine 3 (5-HT3) receptor modulator, preparing for Phase II clinical trials for the treatment of depression. TPN171 is a potential best-in-class, highly efficient, and selective phosphodiesterase 5 (PDE5) inhibitor approved in Uzbekistan for the treatment of erectile dysfunction (ED) and is expected to receive new drug application (NDA) approval from the National Medical Products Administration (NMPA) in China for the same indication.<\/p>\n\n\n\n

Generic Pipeline and Commercialization<\/strong>
In addition to the innovative pipeline, Vigonvita Bio is also advancing a generic pipeline, generating visible, recurring revenue and cash flow streams as a strategic complement to the business, thereby enhancing overall resilience.<\/p>\n\n\n\n

Manufacturing and Commercial Capabilities<\/strong>
Vigonvita Bio’s integrated capabilities are also reflected in its mature manufacturing and commercial capabilities. The company has established a GMP-compliant commercial production facility in Lianyungang, Jiangsu Province, with a total construction area of approximately 51,955 square meters and an annual design capacity of 100 million capsules and 600 million tablets. Vigonvita Bio believes that internal production capabilities can improve the efficiency of development and production processes, enabling the company to achieve reliable quality and cost control and ensure stable, timely clinical and commercial drug supply to cope with any supply chain disruptions. Moreover, Vigonvita Bio’s internal GMP-standard production capabilities will continue to serve as the cornerstone of its ability to rapidly respond to evolving and unpredictable public health emergencies.<\/p>\n\n\n\n

Business Development and Commercialization Team<\/strong>
As of September 30, 2024, Vigonvita Bio has established a dedicated business development and commercialization team of 14 employees, each with an average of over 13 years of industry experience.Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita…<\/p>\n","protected":false},"author":1,"featured_media":23619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[20,72,3240],"class_list":["post-23618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finance","tag-ipo","tag-vigonvita-life-sciences"],"yoast_head":"\nVigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23618\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model\" \/>\n<meta property=\"og:description\" content=\"On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23618\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-28T04:47:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-28T04:47:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model\",\"datePublished\":\"2025-01-28T04:47:54+00:00\",\"dateModified\":\"2025-01-28T04:47:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618\"},\"wordCount\":473,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2801-png.avif\",\"keywords\":[\"Finance\",\"IPO\",\"Vigonvita Life Sciences\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23618#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23618\",\"name\":\"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2801-png.avif\",\"datePublished\":\"2025-01-28T04:47:54+00:00\",\"dateModified\":\"2025-01-28T04:47:57+00:00\",\"description\":\"On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23618\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2801-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2801-png.avif\",\"width\":1080,\"height\":607,\"caption\":\"Suzhou Vigonvita Life Sciences Files for HKEX IPO\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23618#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model - Insight, China's Pharmaceutical Industry","description":"On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23618","og_locale":"en_US","og_type":"article","og_title":"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model","og_description":"On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.","og_url":"https:\/\/flcube.com\/?p=23618","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-28T04:47:54+00:00","article_modified_time":"2025-01-28T04:47:57+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23618#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23618"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model","datePublished":"2025-01-28T04:47:54+00:00","dateModified":"2025-01-28T04:47:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23618"},"wordCount":473,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=23618#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif","keywords":["Finance","IPO","Vigonvita Life Sciences"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23618#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23618","url":"https:\/\/flcube.com\/?p=23618","name":"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=23618#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=23618#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif","datePublished":"2025-01-28T04:47:54+00:00","dateModified":"2025-01-28T04:47:57+00:00","description":"On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23618#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23618"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=23618#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif","width":1080,"height":607,"caption":"Suzhou Vigonvita Life Sciences Files for HKEX IPO"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23618#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2801-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23618"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23618\/revisions"}],"predecessor-version":[{"id":23620,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23618\/revisions\/23620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/23619"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}